Counseling and Peer Support for Opioid Use Disorder

(MOUD+ Trial)

SC
PI
Overseen ByPrincipal Investigator
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Oregon Health and Science University
Must be taking: Buprenorphine
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if adding counseling and peer support to usual care can help people with Opioid Use Disorder (OUD) adhere to their medication and engage more with primary care. Usual care includes medication for OUD, such as buprenorphine, while the new approach, called the MOUD Plus Pilot, provides additional support from counselors and community peers. The trial targets individuals with an OUD-related diagnosis who have recently used opioids like fentanyl or heroin and wish to participate in counseling or peer services. Participants will meet with prescribers, counselors, and peers to support their recovery goals. As an unphased trial, this study offers a unique opportunity to explore new supportive approaches for OUD recovery.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It focuses on adding counseling and peer support to your existing treatment with buprenorphine for opioid use disorder.

What prior data suggests that this program of counseling and peer support is safe for people with Opioid Use Disorder?

Research has shown that the MOUD Plus program, which combines counseling and peer support with standard care, is well-received. A previous study found that participants using MOUD reduced substance use and improved health after six months, indicating the treatment's safety for individuals with opioid use disorder (OUD).

Further research supports the role of peer recovery support in helping individuals remain engaged in their OUD treatment. Staying in treatment is crucial, as it is linked to better health outcomes. These findings suggest that the MOUD Plus program is safe and could benefit those seeking to improve their health and maintain engagement in care.12345

Why are researchers excited about this trial?

Researchers are excited about MOUD Plus because it enhances standard opioid use disorder treatments by adding integrated counseling and peer support. Unlike the usual approach that involves low-threshold medication-assisted treatment in a primary care setting, MOUD Plus provides coordinated warm handoffs to counseling services and community-based peer support. This comprehensive care strategy aims to improve patient outcomes by addressing both the medical and psychosocial aspects of recovery, potentially offering a more holistic and supportive path to overcoming opioid dependency.

What evidence suggests that this trial's treatments could be effective for opioid use disorder?

Research has shown that adding counseling and peer support to standard treatment for opioid use disorder (OUD) can be beneficial. In this trial, participants in the MOUD Plus Arm will receive treatment as usual, which includes medication-assisted treatment like MOUD, along with integrated counseling and peer referral. Studies have found that medication-assisted treatment can reduce drug use and improve both physical and mental health over six months. Specifically, individuals who continued with MOUD after leaving a treatment center had fewer emergency room visits, spent fewer days in the hospital, and experienced fewer overdoses within 90 days. The MOUD Plus Arm aims to help people stay on MOUD and engage more with primary care by combining medication with counseling and peer support. This approach seeks to help individuals adhere to their treatment and achieve better overall health.12567

Who Is on the Research Team?

BC

Brian Chan, MD MPH

Principal Investigator

Oregon Health and Science University

Are You a Good Fit for This Trial?

This trial is for individuals with Opioid Use Disorder (OUD) who also have other medical conditions. They should be seeking care in primary care settings and are willing to engage in a program that includes medication, counseling, and peer support.

Inclusion Criteria

Who meet at least one of the following criteria:
Medical complexity (e.g. self-reported or verified in patient's electronic health record)
I have been diagnosed with or have used opioids like fentanyl or heroin in the last 30 days.
See 5 more

Exclusion Criteria

Patients who participated in Aim 2 would not be eligible for Aim 3
Patients who do not have addiction to opioids may not participate in the study
Patients with severe and persistent mental illness (e.g., diagnosis of psychosis, schizophrenia, or bipolar) may not participate in the study
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive the MOUD Plus intervention, including counseling and peer support, alongside usual primary care with buprenorphine

6 months
Visits every 2-4 weeks with prescribers, plus additional meetings with counselors and peers

Follow-up

Participants are monitored for retention on MOUD and engagement with care teams, with assessments at 2, 3, and 6 months

6 months
Follow-up surveys at 2, 3, and 6 months

What Are the Treatments Tested in This Trial?

Interventions

  • MOUD Plus Pilot
Trial Overview The study tests if adding coordinated counseling and community-based peer support to usual primary care improves patient retention on buprenorphine (a medication for OUD) and engagement in primary care compared to standard treatment.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: MOUD Plus Arm (treatment as usual + integrated counseling and peer referral)Experimental Treatment1 Intervention
Group II: Treatment as usual Arm (low threshold MOUD prescribing in primary care)Active Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Oregon Health and Science University

Lead Sponsor

Trials
1,024
Recruited
7,420,000+

National Institute on Drug Abuse (NIDA)

Collaborator

Trials
2,658
Recruited
3,409,000+

Central City Concern

Collaborator

Trials
2
Recruited
270+

Published Research Related to This Trial

The low-threshold group-based MOUD program at a federally qualified health center in Philadelphia effectively increased patient access and retention through its person-centered harm reduction approach and integration into primary care.
Challenges included varying staff acceptance of harm reduction principles and the need to manage clinic workflow, highlighting the importance of understanding both strengths and challenges for similar programs in other clinics.
"It's a place that gives me hope": A qualitative evaluation of a buprenorphine-naloxone group visit program in an urban federally qualified health center.Lai, S., Li, E., Silverio, A., et al.[2022]
A qualitative study involving 26 patients receiving methadone treatment found that a peer recovery specialist-delivered behavioral activation intervention (Peer Activate) was perceived as acceptable and feasible, particularly due to its flexibility and the supportive qualities of the peer specialists.
Participants highlighted the importance of connecting with the intervention content and building skills, while also noting stigma related to substance use and methadone treatment as barriers to engagement, suggesting that addressing these issues could enhance treatment retention.
"You rise up and then you start pulling people up with you": Patient experiences with a peer-delivered behavioral activation intervention to support methadone treatment.Kleinman, MB., Hines, AC., Anvari, MS., et al.[2023]
The tailored telephone intervention delivered by peers (TTIP-PRO) was well-received by participants, with all eight patients finding it 'very helpful' and showing a significant increase in their knowledge about opioid overdoses, from 69.9% to 93.6% correct responses after the intervention.
While interest in starting medication-assisted treatment (MAT) increased from 8.1 to 9.5 on a 10-point scale, this change was not statistically significant, indicating that further development and testing of TTIP-PRO is needed to effectively encourage MAT enrollment.
Development and initial testing of a tailored telephone intervention delivered by peers to prevent recurring opioid-overdoses (TTIP-PRO).Winhusen, T., Theobald, J., Lewis, D., et al.[2022]

Citations

Outcomes from the medication assisted treatment pilot ...This study shows decreased substance use, improved physical and mental health, and reduced symptoms after 6 months of MOUD.
Smartphone App–Based Contingency Management and ...Although MOUD is often effective at reducing personal and societal harms, some patients still experience difficulties with continued opioid use ...
Outcomes from the medication assisted treatment pilot ...This study shows decreased substance use, improved physical and mental health, and reduced symptoms after 6 months of MOUD.
Counseling and Peer Support for Opioid Use Disorder ...Patients who adhered to MOUD after discharge experienced notable reductions in emergency department visits, inpatient days, and opioid overdoses within 90 days ...
Medications for Opioid Use Disorder (MOUD) StudyThe MOUD study examined patient outcomes from several opioid use disorder (OUD) treatments.
Full article: Virtual reality-based Mindfulness-Oriented ...Participants reported high usability and acceptability of MORE-VR, which had an excellent safety profile. Illicit opioid use decreased ...
The MOUD “PLUS” Study: Collaborating with Recovery ...The MOUD PLUS study aims to improve care engagement and retention for people with OUD seen in primary care. The study pilots implementation of ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security